Highlights
On October 9, the official website of CDE showed that the bisoprolol amlodipine tablets of Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. and Hunan Sheng Pharmaceutical Co., Ltd. were under review as a generic type 4. According to data from Minenet, the sales scale of bisoprolol amlodipine tablets in China's three major terminals and six major markets (see the end of the article for statistical scope) has expanded rapidly in recent years, with a year-on-year increase of 231.19% in 2023.
Bisoprolol amlodipine tablets are used as an alternative therapy to the treatment of hypertension in patients who are currently taking the same dose of single agent as the combination formulation and have good blood pressure control.
Sales of bisoprolol amlodipine tablets in China's three major terminals and six major markets in recent years (unit: 10,000 yuan)
Source: Minenet Grid Bureau Database
In recent years, the sales scale of bisoprolol amlodipine tablets in China's three major terminals and six major markets has expanded rapidly, and although it will be less than 20 million yuan in 2023, the growth rate will be amazing, reaching 231.19%.
According to the data of Minenet, there are 3 companies with production approvals for bisoprolol amlodipine tablets, and in April this year, Yuandong Biology won the first imitation; In May, Shijiazhuang No. 4 Pharmaceutical became the second domestic company. At present, there are 25 enterprises under review, of which 21 companies, including Guangdong Fangsheng Jianmeng Pharmaceutical, Hunan Shengsheng Pharmaceutical, Shandong New Era Pharmaceutical, and Chengdu Beite Pharmaceutical, are all reporting production this year.
Fangsheng Pharmaceutical's approval of hypertensive chemical drug products
Source: Minenet China Listed Drugs (MID) Database
Up to now, Fangsheng Pharmaceutical has 3 product production approvals in the field of hypertension chemical drugs, among which, irbesartan hydrochlorothiazide tablets will be a blockbuster variety of nearly 2 billion yuan in China's three major terminal and six major markets in 2023, and the TOP8 products of hypertension chemical drugs.
Source: CDE official website, Minenet database
Note: The statistical scope of "Drug Competition Pattern of China's Three Terminals and Six Major Markets" by Minenet is: urban public hospitals and county-level public hospitals, urban community centers and township health centers, urban physical pharmacies and online pharmacies, excluding private hospitals, private clinics, village clinics, and county and rural pharmacies; The above sales are calculated based on the average retail price of the product at the terminal.